Chile observatory captures the universe with 3,200-megapixel camera
SANTIAGO (Reuters) -Chile's Vera C. Rubin Observatory, which boasts the world's largest digital camera, has begun displaying its first images of the cosmos, allowing astronomers to figure out how the solar system formed and even whether an asteroid poses a threat to Earth.
Located on Pachon Hill in the northern region of Coquimbo, the 8.4-meter (27-1/2-foot) telescope has a 3,200-megapixel camera feeding a powerful data processing system.
"It's really going to change and challenge the way people work with their data," said William O'Mullane, a project manager focused on data at Vera Rubin.
The observatory detected over 2,100 previously unseen asteroids in 10 hours of observations, focusing on a small area of the visible sky. Its ground-based and space-based peers discover in total some 20,000 asteroids a year.
O'Mullane said the observatory would allow astronomers to collect huge amounts of data quickly and make unexpected finds.
"Rather than the usual couple of observations and writing an (academic) paper. No, I'll give you a million galaxies. I'll give you a million stars or a billion even, because we have them: 20 billion galaxy measurements," he said.
The center is named after American astronomer Vera C. Rubin, a pioneer in finding conclusive evidence of the existence of large amounts of invisible material known as dark matter.
Each night, Rubin will take some 1,000 images of the southern hemisphere sky, letting it cover the entire southern sky every three or four nights. The darkest skies above the arid Atacama Desert make Chile one of the best places worldwide for astronomical observation.
"The number of alerts the telescope will send every night is equivalent to the inboxes of 83,000 people. It's impossible for someone to look at that one by one," said astrophysicist Francisco Foster.
"We're going to have to use artificial intelligence tools."
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
UPI
2 hours ago
- UPI
Defense Department to end satellite data programs used for storm forecasts
1 of 2 | Two Department of Defense satellite programs that supplied data used by the National Oceanic and Atmospheric Administration as part of hurricane forecasting are being discontinued, according to the agency. U.S. Navy photo via Naval Research Laboratory June 28 (UPI) -- With the of peak hurricane season looming, forecasters will be without key information starting Monday because the Defense Department said it will no longer provide them with data from the weather satellites. The National Oceanic and Atmospheric Administration published a notice Wednesday about the change. "Due to recent service changes, the Defense Meteorological Satellite Program (DMSP) and Navy's Fleet Numerical Meteorology and Oceanography Center (FNMOC) will discontinue ingest, processing and distribution of all DMSP data no later than June 30, 2025," the notice said. "This service change and termination will be permanent." This change is coming amid cuts in staffing at NOAA, as well as reductions in scientific programs. One unidentified NOAA scientist told The Guardian the changes amount to a "systemic destruction of science." For 40 years, the Pentagon has operated satellites for atmospheric and ocean conditions. There are three now. The satellites gather multiple wavelengths of light, including visible, infrared, microwave, Kim Wood, an atmospheric scientist at the University of Arizona, told Scientific American. Microwaves are used to monitor hurricanes, Wood said, "because the waves are so long they get through the tops of the clouds" and help scientists to understand a storm's inner workings, especially those that occur at night. The U.S. Navy's Fleet Numerical Meteorology and Oceanography Center processes raw data, which is then used by scientists and forecasters for real-time data. The satellites also are used to collect data on sea ice in polar regions. A U.S. Space Force spokesperson said in a statement that the satellites and instruments are functional and that the Department of Defense will continue to use them while access for scientists is cut off. The agency uses data to track conditions for its ships. "It's not an issue of funding cuts," Mark Serreze, the director of the National Snow and Ice Data Center, a federally funded research center in Colorado, told NPR. "There are cybersecurity concerns. That's what we're being told." With the data, hurricane experts can see where the center of a storm forms, and hence figure out the direction where it could be headed, including land. Also, they can see when a new eyewall forms, which helps determine intensity. That was done with Hurricane Erick earlier this month in the Pacific Ocean. The National Hurricane Center, which is overseen by NOAA, doesn't expect less-accurate forecasts. "NOAA's data sources are fully capable of providing a complete suite of cutting-edge data and models that ensure the gold-standard weather forecasting the American people deserve," NOAA communications director Kim Doster told NPR. NOAA and NASA also operate satellites that are used for forecasts. Brian Tang, a hurricane researcher at the University at Albany, told NPR that it is important to have as many data sensors as possible. "I was surprised, given how important it is for forecasting hurricanes and monitoring important features like sea ice," Tang said. "This is data that forecasters use regularly." "We're a bit blind now," said Allison Wing, a hurricane researcher at Florida State University, told The Guardian. "Before these types of satellites were present, there would often be situations where you'd wake up in the morning and have a big surprise about what the hurricane looked like," she said. "Given increases in hurricane intensity and increasing prevalence towards rapid intensification in recent years, it's not a good time to have less information." The hurricane season runs from June 1 to Nov. 30 with five so far named in the Pacific and one so far in the Atlantic.
USA Today
4 hours ago
- USA Today
Texas politicians lead effort to study a psychedelic drug. What is ibogaine?
Ibogaine is illegal in the U.S., but growing evidence shows its promise treating the effects of traumatic brain injury and substance use disorder. A once obscure traditional psychedelic plant from Africa has made headlines recently as Texas pushes for more research and a prominent Republican wrote a vigorous endorsement of its possible use for the treatment of addiction and for veterans experiencing mental health issues. Ibogaine is illegal for use in the United States, but a growing body of evidence has shown its promise treating the effects of traumatic brain injury and substance use disorder. Earlier in June, Texas Gov. Greg Abbott signed legislation to allocate $50 million for clinical trials approved by the Food and Drug Administration to study ibogaine. Texas is set to lead research into the drug's benefits treating mental health issues and addiction as a potential medication. Former Energy Secretary Rick Perry, also a former Texas governor, wrote a June 27 Washington Post op-ed supporting ibogaine research and criticizing the legacy of the war on drugs, started by President Richard Nixon and touted by President Ronald Reagan. Perry said he has 'come to realize just how wrong that narrative was.' 'That fear-based messaging kept us from exploring treatments that could have saved countless lives,' Perry wrote. Perry and a growing number of conservatives have argued ibogaine could be one of those treatments. Here's what to know about the drug. What is ibogaine? Ibogaine derives from the root of the iboga plant native to western-central Africa. It's been used in ceremonial rituals for centuries. It has hallucinogenic properties. The United States outlawed ibogaine in 1967 along with other psychotropic drugs. The Controlled Substances Act of 1970 placed it as a schedule I hallucinogenic drug, along with marijuana. Ibogaine's classification prevented researchers from studying its effects. But unlike other schedule 1 drugs such as heroin, ibogaine has anti-addictive properties. There are risks since ibogaine can delay the body's normal electrical signals that control heart rhythm, which could lead to death. Other countries, such as Mexico, have allowed its use. American veterans and others have traveled to smaller, clandestine clinics for treatment to deal with depression, post-traumatic stress disorder and addiction. Many clinics are along the border and around cities such as Tijuana. Why is it in the news? At the state and federal level, there is growing interest in studying psychedelic drugs to treat veterans and others. Texas passed legislation earlier in June to study the drug with a public university alongside a company and hospital, Abbott's office said. Dr. Marty Makary, the FDA commissioner, has said expanding research on psychedelic drugs is a top priority for the Trump administration. In his op-ed, Perry cited the experiences of Morgan and Marcus Luttrell, twin combat veterans, who used ibogaine for recovery. Morgan Luttrell is now a Republican congressman from Texas who has advocated for ibogaine and other psychedelic drugs as treatment options. In January 2025, Perry and W. Bryan Hubbard, an advocate for ibogaine treatment, appeared on Joe Rogan's podcast to discuss ibogaine's benefits as a plant-based medicine. Hubbard led a Kentucky task force that sought to use opioid settlement funds to research ibogaine's effects to treat addiction, but the initiative failed to gain support in the state. Hubbard and Perry eventually launched the Texas Ibogaine Initiative, which helped spur the state funding. What has research shown? Research, such as a Stanford University study of 30 male combat veterans, has shown ibogaine's promise. Coupled with magnesium sulfate to address heart effects, ibogaine appeared to reduce symptoms of PTSD, anxiety and depression, and improve cognitive function from traumatic brain injury, according to the study, published in 2024 in the eminent journal Nature Medicine. Other studies have shown benefits treating addiction and depression. What do critics say? One issue with ibogaine is the ability to produce it, because it is derived from a rare plant and has mostly been used for ceremonial purposes. There is research to help innovate its safe production, but it could be difficult for the drug to be more widely available, as researchers at the University of California, Davis, Institute for Psychedelics and Neurotherapeutics have said. And while it's shown benefits with combat veterans, questions remain on its efficacy among randomized participants. With Texas' research, ibogaine could get closer to FDA approval for its use as a medication.
Newsweek
4 hours ago
- Newsweek
This New Test Could Diagnose Parkinson's With AI
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. A new artificial intelligence (AI) tool analyzing short smile videos achieved high accuracy in screening for Parkinson's disease (PD), according to research published by Tariq Adnan, and colleagues in the New England Journal of Medicine (NEJM) Thursday. The model was trained on the largest known video dataset of facial expressions to date, enrolling 1,452 participants, including 391 living with PD. An 87.9 percent overall accuracy in detecting PD using only smile video analysis, the NEJM AI study reported. Researchers reported that the AI model could accurately distinguish between individuals with and without PD based on the analysis of their smiles, even when applied in diverse population samples from North America and Bangladesh. Why It Matters The Parkinson's Foundation says an estimated 90,000 more people will be diagnosed this year, with the number of those suffering expected to be around 1.2 million by 2030. Diagnosing Parkinson's disease early remains a significant challenge because of limited access to clinical expertise and in-person evaluations. AI-driven remote screening tools promise scalable, cost-effective solutions to bridge these healthcare gaps. The findings align with the growing demand for digital healthcare solutions that remove geographical and economic barriers to early neurological disease diagnosis, which is especially relevant to rural and underserved American communities. What To Know The new screening method invited participants to record themselves mimicking facial expressions—including a smile—using an online platform. Research teams then extracted facial landmarks and measured action units to quantify hypomimia, a common motor symptom in PD where facial muscle movement is diminished. Machine learning models were developed using these features, distinguishing people with PD from those without. The approach relied on a broad recruitment strategy, involving participants from North America via social media, email, wellness centers, and research registries, alongside a high-risk cohort from Bangladesh. Trained solely on smile videos, the model achieved a 10-fold cross-validated accuracy of 87.9 percent, a sensitivity of 76.8 percent, and a specificity of 91.4 percent. Validation in external test sets revealed 80.3 percent accuracy in a U.S. clinic dataset and 85.3 percent accuracy in the Bangladesh cohort. While the negative predictive value remained above 92 percent in all settings, the positive predictive value dropped to 35.7 percent among the Bangladeshi participants, reflecting variations in population characteristics. The study found no significant differences in model performance across sex and ethnic subgroups, except for marginally higher accuracy in female participants in Bangladesh. The authors emphasized the generalizability and fairness of the approach, key considerations in the development of clinical AI tools. The video-processing and machine-learning code supporting the study is available to the public on GitHub. However, the study authors noted that raw video data sharing is restricted to comply with U.S. healthcare privacy law (HIPAA), limiting access to de-identified derivative features only. The research received funding from the National Institute of Neurological Disorders and Stroke at the National Institutes of Health, among other sources. The work was a collaborative effort involving academic and clinical partners such as the InMotion Parkinson's Disease wellness center and the University of Rochester Center for Health and Technology. The research process also benefited from contributions by staff at Google Research and the University of Rochester, particularly in statistical analysis. Stock image of brain MRI taken November 21, 2018. Stock image of brain MRI taken November 21, 2018. Getty What People Are Saying Tariq Adnan, lead author said in the study conclusion: "Smiling videos can effectively differentiate between individuals with and without PD, offering a potentially easy, accessible, and cost-efficient way to screen for PD, especially when access to clinical diagnosis is limited." What Happens Next? Future steps for the research team involve wider validation of the AI screening method in additional, real-world populations and further refinement of the algorithm to maximize early detection accuracy. Regulatory and clinical translation pathways will determine if and when this technology becomes available in the United States healthcare system.
